Generic Drugs

Anti-Epileptic Drug (MD09)

MD09 is a Pyrrolidone derivative, categorized as a small-molecule injectable medication.

Market Potential：MD09 is a widely utilized global anti-epileptic drug employed in the treatment of various forms of epilepsy, including partial seizures, generalized seizures, complex seizures, and epileptic syndromes. It is suitable for epilepsy patients who are temporarily unable to take oral anti-epileptic medications or those who experience adverse reactions to other drugs. In 2022, MD09 achieved sales of 240 million NTDs in the Taiwan market and 26 million US Dollars in the Southeast Asian market. The target market exhibited a Compound Annual Growth Rate (CAGR) of approximately 11% from 2018 to 2022.

Emergency-Use Medication (MD13)

MD13, classified as epinephrine, a vital neurotransmitter, serves the pivotal function of constricting blood vessels and elevating blood pressure. This medication is indispensable in emergency situations, specifically for addressing acute hypotension and cardiac arrest.

Market Potential：MD13 plays a critical role in emergency and urgent medical situations, such as shock, trauma, or severe infections, where it is used to rapidly increase blood pressure and ensure adequate blood supply to vital organs. In cases of cardiac arrest or bradycardia, MD13 is administered to reestablish heart function. In 2022, MD13 demonstrated impressive sales figures, amounting to 130 million NTDs within the Taiwanese market, 40 million US Dollars in the Southeast Asian market, and an impressive global market value of 400 million US Dollars.

Central Diabetes Insipidus Drug (MD19)

MD19 is a peptide medication for the treatment of central diabetes insipidus, a condition characterized by excessive thirst and urination. It is a synthetic hormone composed of nine amino acids and exhibits superior antidiuretic properties compared to naturally occurring vasopressin in the human body. This medication presents challenges in terms of low component concentrations and multiple derivatives, demanding a high level of analytical expertise and product quality consistency.

Market Potential：MD19 is indicated for the treatment of central diabetes insipidus, hemophilia A, and von Willebrand disease (von Willebrand-Jürgens syndrome). It is listed in the World Health Organization's Essential Medicines List, recognized as an essential and safe medication within healthcare systems. MD19 achieved sales of 40 million US Dollars in the United States and approximately 40 million NTDs in the Taiwanese market in 2022. Globally, MD19 maintains a stable market presence, with global sales reaching 60 million US Dollars in the same year.

Anti-Infective Medication (MD20)

MD20 is a lipopeptide-class antifungal medication that exerts its therapeutic effect by disrupting enzyme activity involved in fungal cell wall synthesis, effectively inhibiting fungal growth. To address the challenge of poor water stability in its active ingredients, MD20 is meticulously formulated as a freeze-dried preparation to enhance product stability.

Market Potential：MD20 is a broad-spectrum antifungal medication and holds the distinction of being the first FDA-approved inhibitor of fungal (1→3)-β-D-glucan synthesis. Its significance in the field of medicine is underscored by recommendations from the Infectious Diseases Society of America.They endorse MD20 for use in immunocompromised patients, such as those with acute myeloid leukemia, to prevent fungal infections during induction chemotherapy, thereby bolstering the chances of successful cancer treatment. Furthermore, MD20 also serve as salvage therapy for other fungal infections, especially when patients are insensitive to or intolerant of other antifungal medications. MD20 has consistently maintained a robust presence in the global market, with annual sales surpassing the 500 million US Dollars mark between 2018 and 2022.

Prostate Cancer Inhibitor (MD21)

MD21, composed of nine amino acids, is an analogue of gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LH-RH). It effectively suppresses the secretion of sex hormones. Notably, MD21 falls into the category of peptide drugs, which have a higher development threshold compared to conventional small-molecule drugs. Moreover, MD21 is a combination product of medical devices and pharmaceuticals, subject to rigorous compliance with both medical device and pharmaceutical regulations.

Market Potential：MD21 serves as a critical therapeutic intervention in palliating conditions such as prostate cancer, endometriosis, central precocious puberty, profuse menstrual bleeding, and anemia stemming from uterine fibroids in patients anticipating surgical procedures. Additionally, it proves beneficial in managing premenopausal breast cancer, among other applications. Remarkably, in 2022, MD21 recorded remarkable sales amounting to 1.2 billion US Dollars in the United States, with an average CAGR of approximately 7% over the period from 2018 to 2022.

Anti-Infective Medication (MD22)

MD22 is a compound belonging to the triazole class, serving as a widely-used broad-spectrum antifungal medication with excellent inhibitory effects against Candida strains. MD22 is formulated as a freeze-dried preparation with a high filling volume, presenting considerable challenges in its manufacturing process.

Market Potential：MD22 is endorsed in the latest guidelines by the Infectious Diseases Society of America for the treatment of fungal infections. It is recommended for confirmed cases of invasive fungal infections, prophylactic use, and as an empirical therapy option. MD22 maintains a stable global market presence, with annual sales reaching 300 million US Dollars from 2018 to 2022.

Sustained-Release Medication (MD23)

MD23 is a synthetic peptide drug comprised of 8 amino acids, organized into a cyclic compound. Its molecular structure closely mirrors that of hormones naturally occurring in the human body, yet it demonstrates an elevated level of physiological activity. When paired with our long-acting platform, MD23 forms a drug-polymer complex, allowing for the gradual release of the medication through the polymer's degradation and diffusion processes. This unique mechanism ensures sustained therapeutic effects for a duration of up to one month.

Market Potential：MD23 holds promise for a wide range of medical conditions, including acromegaly, functional gastrointestinal and pancreatic neuroendocrine tumors, among others. By leveraging the sustained-release platform, MD23 reduces dosing frequency, enhancing treatment convenience. In 2022, MD23 achieved sales of 800 million US Dollars in the United States, 400 million NTDs in Taiwan, and a global market value of 1.5 billion US Dollars.

Schizophrenia Medication (MD27)

MD27 falls within the second generation of antipsychotic medications, commonly referred to as atypical antipsychotics, and is utilized for the management of diverse psychiatric conditions. Its mode of action encompasses interactions with multiple neurotransmitter receptors, including dopamine and serotonin receptors. Notably, in contrast to other antipsychotic drugs, MD27 often provides a more rapid alleviation of symptoms.

Market Potential：MD27 is primarily employed in the treatment of schizophrenia and bipolar disorder (commonly known as manic depression). By modulating neural signals, it reduces the symptoms associated with schizophrenia and other related mental illnesses. In 2022, MD27 generated sales of 30 million US Dollars in the United States and had a global market value of 150 million US Dollars.

HIV Combination Tablet (NDF01) [505b2 New Drug]

The treatment approach for HIV has undergone a transformation, shifting from traditional regimens that relied on combining several individual drugs to the adoption of combination tablets. This not only bolster treatment efficacy but also mitigate side effects, alleviating the psychological resistance that often arises with the requirement for multiple drug administrations. Consequently, they significantly enhance medication adherence.

Within Taiwan, the majority of HIV combination medications are imported, revealing a deficiency in indigenous capacity for development and production. NDF01, a a dual-layer tablet designed and developed independently by UBI Pharma Inc. could prevent potential interactions among active ingredients, boasts as a groundbreaking combination drug.

Market Potential：NDF01 can serve as a frontline treatment in the diverse cocktail therapies for HIV. Specifically formulated for HIV patients with concurrent tuberculosis co-infection, approximately 2,457 individuals in Taiwan could benefit from this medication. Based on the daily medication cost per patient, the potential market size for NDF01 in Taiwan alone exceeds NT$375 million annually.